Health Canada approves Moderna's mRNA RSV vaccine, company says
Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...
Could mRNA vaccines conquer another deadly infection? Researchers say yes
They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...
Acsh.org1d
Don’t Be Afraid of mRNA Vaccines
With the possibility of Robert F. Kennedy, Jr. being involved in health policy in the next administration, vaccination – ...
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Moderna swings to profits as new COVID shot powers Q3 beat
Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
Buy, Sell, Or Hold MRNA Stock?
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...
Newly described anti-viral defense system in bacteria aborts infection by chemically altering mRNA
Like humans and other complex multicellular organisms, single-celled bacteria can fall ill and fight off viral infections. A ...
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Moderna price target lowered to $111 from $125 at Barclays
Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...
Moderna’s Mixed Performance: Strong Spikevax Sales Drive Q3 Success Amid mRESVIA Uncertainties, Resulting in Hold Rating
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
The Independent Singapore4d
Singapore opens Asia’s first automated mRNA production facility
SINGAPORE: In a bid to bolster Singapore’s healthcare resilience, the country has launched Asia’s first fully automated mRNA ...